Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Century Therapeutics, Inc. (NASDAQ: IPSC) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory documents, including Forms 10-K, 10-Q, 8-K and other submissions. These filings offer detailed information on Century Therapeutics’ iPSC-derived cell therapy pipeline, financial position and material corporate events.
Century Therapeutics uses its SEC reports to describe its focus on autoimmune diseases, cancer and Type 1 diabetes, its Allo-Evasion™ immune evasion technology, and programs such as CNTY-101, CNTY-308 and CNTY-813. Current reports on Form 8-K have disclosed items like private placement financing arrangements, Nasdaq listing status developments, workforce reductions, board and executive changes, and earnings press releases.
Through periodic filings such as Forms 10-Q and 10-K, investors can review Century Therapeutics’ reported cash, cash equivalents and investments, research and development and general and administrative expenses, collaboration revenue recognition and accumulated deficit. Risk factor and business sections in these reports provide the company’s own discussion of uncertainties related to clinical development, regulatory approvals, collaborations and market conditions.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand the implications of new documents. Real-time updates from EDGAR ensure that new IPSC filings, including 8-Ks on material events and any Form 4 insider transaction reports, are added as they become available. Use this page to navigate directly to the filings most relevant to your analysis of Century Therapeutics’ business, pipeline and capital structure.
Century Therapeutics SVP Finance & Operations Douglas Carr reported a small automatic share sale linked to equity compensation. On February 3, 2026, he sold 323 shares of Common Stock at $1.822 per share to cover tax withholding obligations from vesting restricted stock units.
After this tax-related sale, Carr beneficially owned 514,551 shares of Century Therapeutics common stock, held directly. The filing explains that the transaction was executed automatically and was not made at his discretion.
Century Therapeutics, Inc. is registering 176,086,947 shares of common stock for resale by existing investors following a January 7, 2026 private placement. The shares include PIPE stock plus shares issuable from pre-funded and common warrants.
This is a secondary offering, so Century will not receive proceeds from any stockholder sales, though it may receive cash if warrants are exercised. Century develops off‑the‑shelf iPSC-derived cell therapies for autoimmune diseases and cancer, with lead programs CNTY‑813 for Type 1 diabetes, CNTY‑308 for B‑cell diseases, and CNTY‑101 for B‑cell‑mediated autoimmune diseases.
Century Therapeutics President and CEO Brent Pfeiffenberger received new equity awards. On February 2, 2026, he was granted 475,000 shares of common stock in the form of restricted stock units at a price of
He also received a stock option for 945,000 shares of common stock at an exercise price of
Century Therapeutics, Inc. reported that Chief Technology and Manufacturing Officer Gregory Russotti received new equity awards. On February 2, 2026, he was granted 135,000 shares of common stock in the form of restricted stock units at $0 per share, increasing his directly held common stock to 525,982 shares. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over the following three years, subject to his continued service.
Russotti was also granted a stock option for 265,000 shares of common stock at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the balance in 36 equal monthly installments thereafter. In addition, 92,773 shares of common stock are reported as indirectly owned through the Gregory Russotti 2021 Family Trust.
Century Therapeutics Chief Scientific Officer Chad Cowan received new equity awards in the form of restricted stock units and stock options. On February 2, 2026, he was granted 135,000 restricted stock units at no cash cost, increasing his directly held common stock to 1,178,476 shares. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over the following three years, subject to his continued service. He was also granted a stock option covering 265,000 shares of common stock at an exercise price of
Century Therapeutics reported that Douglas Carr, its SVP Finance & Operations, received equity awards. He was granted 110,000 restricted stock units, each representing one share of common stock, vesting 25% on February 2, 2027 and the remaining 75% quarterly over three years, subject to continued service.
He was also granted a stock option for 225,000 shares at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the remaining 75% in 36 equal monthly installments, expiring on February 2, 2036. After these grants, he beneficially owns 514,874 common shares directly and 225,000 options.
Century Therapeutics, Inc. held a special stockholder meeting where investors approved an amendment to its charter that would allow a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-30, at the discretion of the board. The proposal received 55,089,478 votes for, 5,361,020 against, and 27,055 abstentions, indicating strong support for the potential split. On the same day, the company received notice from the Nasdaq Stock Market that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. Because the company is now in compliance with all continued listing standards, it does not intend to implement the reverse stock split that stockholders approved.
Century Therapeutics, Inc. received a Schedule 13G from RA Capital Management and related parties reporting a significant passive ownership position. RA Capital Healthcare Fund directly holds 17,754,430 shares of common stock, plus pre-funded warrants exercisable for up to 8,332,526 shares and additional warrants exercisable for up to 13,043,478 shares of common stock. A beneficial ownership blocker in these warrants limits the group’s exercisability so that total beneficial ownership does not exceed 9.99% of Century’s common stock, which is currently 17,944,649 shares.
The 9.99% figure is calculated using 87,405,311 shares outstanding as of November 25, 2025, plus 92,030,595 shares issued in a January 9, 2026 private placement and 190,219 shares issuable upon warrant exercise. RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and individuals Peter Kolchinsky and Rajeev Shah report shared voting and dispositive power over these securities and certify they are not holding them to change or influence control of Century Therapeutics.
Century Therapeutics, Inc. received a Schedule 13G from a group of Venrock-affiliated investment entities and individuals reporting a significant ownership position. The group reports beneficial ownership of 13,043,478 shares of common stock (including shares underlying warrants that are immediately exercisable for 4,347,826 shares), representing 7.1% of the common stock. The holdings are spread across Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., and related management entities, with Nimish Shah and Bong Koh as voting members of the managing entities. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics.
Century Therapeutics, Inc. (IPSC) received a Schedule 13G filing from Commodore Capital and related parties. The filing reports beneficial ownership of 13,043,478 shares of Century Therapeutics common stock, representing 7.1% of the outstanding class.
The position consists of 8,695,652 shares of common stock plus 4,347,826 additional shares underlying a warrant. Ownership percentages are based on 179,337,686 shares outstanding as of January 9, 2026, plus the warrant shares. Commodore Capital LP, Commodore Capital Master LP, and individuals Robert Egen Atkinson and Michael Kramarz share voting and dispositive power over the reported shares.
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics, which is why the stake is reported on a Schedule 13G instead of a control‑oriented Schedule 13D.
FAQ
What is the current stock price of Century Therapeutics (IPSC)?
What is the market cap of Century Therapeutics (IPSC)?
